Activation of the PPARγ pathway in MPs is generally considered to be antiinflammatory (67, 68), and there is consensus for a beneficial effect of systemic PPARγ agonist treatment in a wide range of diseases, including diabetes and its comorbidities. This evidence concerns the gene PPARG and diabetes mellitus.